World's Best Scientists 2026 revealed!

Li Zhang publications per year

The chart shows the history of publications by Li Zhang between 2003 and 2025, highlighting the no. of papers published in each year and offering an overview of the publication velocity of this scholar. Li Zhang published across 23 years, from 2003 to 2025, averaging 19.3 papers a year. Output peaked at 65 publications in 2024. 127 of the 445 publications appeared in the last two years.

No. of publications
20 40 60
Bar chart. Horizontal axis: year, 2003 to 2025. Vertical axis: number of publications, 0 to 65. Peak 65 publications in 2024. 2003: 2 publications 2004: 1 publication 2005: 5 publications 2006: 2 publications 2007: 3 publications 2008: 2 publications 2009: 3 publications 2010: 5 publications 2011: 9 publications 2012: 17 publications 2013: 10 publications 2014: 16 publications 2015: 17 publications 2016: 26 publications 2017: 25 publications 2018: 22 publications 2019: 23 publications 2020: 29 publications 2021: 26 publications 2022: 23 publications 2023: 52 publications 2024: 65 publications 2025: 62 publications
2003 2025

445 publications in total across all disciplines

View publications per year as a table
Li Zhang: publications per year, 2003 to 2025
Year Publications
2003 2
2004 1
2005 5
2006 2
2007 3
2008 2
2009 3
2010 5
2011 9
2012 17
2013 10
2014 16
2015 17
2016 26
2017 25
2018 22
2019 23
2020 29
2021 26
2022 23
2023 52
2024 65
2025 62
Total 445
Download as CSV

Li Zhang publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Li Zhang sits on this spectrum.

No. of scientists
200 400 600 800
Bar chart with 86 bars. Horizontal axis: publications, 101–120 to 1,796+. Vertical axis: number of scientists, 0 to 922. Most scientists, 922, have 341–360 publications. The last bar groups every scientist with 1,796 publications or more. 101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 610 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101–120 publications 1,796+

The last bar groups every scientist with 1,796 publications or more.

View publications distribution as a table
Number of Medicine scientists by publication count, Research.com 2026 ranking edition. Based on 20,134 ranked scientists.
Publications Scientists
101–120 5
121–140 26
141–160 73
161–180 155
181–200 230
201–220 363
221–240 487
241–260 545
261–280 722
281–300 768
301–320 834
321–340 895
341–360 922
361–380 838
381–400 861
401–420 918
421–440 806
441–460 771
461–480 751
481–500 713
501–520 617
521–540 610
541–560 537
561–580 504
581–600 509
601–620 396
621–640 386
641–660 371
661–680 340
681–700 336
701–720 307
721–740 259
741–760 230
761–780 228
781–800 217
801–820 204
821–840 186
841–860 177
861–880 155
881–900 139
901–920 145
921–940 116
941–960 133
961–980 91
981–1,000 96
1,001–1,020 77
1,021–1,040 70
1,041–1,060 63
1,061–1,080 77
1,081–1,100 49
1,101–1,120 54
1,121–1,140 49
1,141–1,160 51
1,161–1,180 35
1,181–1,200 39
1,201–1,220 26
1,221–1,240 37
1,241–1,260 36
1,261–1,280 27
1,281–1,300 32
1,301–1,320 28
1,321–1,340 17
1,341–1,360 30
1,361–1,380 28
1,381–1,400 17
1,401–1,420 21
1,421–1,440 15
1,441–1,460 12
1,461–1,480 12
1,481–1,500 18
1,501–1,520 14
1,521–1,540 17
1,541–1,560 15
1,561–1,580 6
1,581–1,600 2
1,601–1,620 12
1,621–1,640 11
1,641–1,660 8
1,661–1,680 5
1,681–1,700 5
1,701–1,720 10
1,721–1,740 12
1,741–1,760 14
1,761–1,780 6
1,781–1,795 5
1,796+ 100
Download as CSV

Li Zhang D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Li Zhang sits on this spectrum.

No. of scientists
250 500 750 1,000
Bar chart with 75 bars. Horizontal axis: D-Index, 70–71 to 217+. Vertical axis: number of scientists, 0 to 1,027. Most scientists, 1,027, have 82–83 D-Index. The last bar groups every scientist with 217 D-Index or more. 70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 399 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70–71 D-Index 217+

The last bar groups every scientist with 217 D-Index or more.

View D-Index distribution as a table
Number of Medicine scientists by D-index, Research.com 2026 ranking edition. Based on 20,134 ranked scientists.
D-Index Scientists
70–71 226
72–73 391
74–75 574
76–77 730
78–79 891
80–81 972
82–83 1,027
84–85 1,003
86–87 960
88–89 970
90–91 922
92–93 839
94–95 808
96–97 779
98–99 668
100–101 611
102–103 630
104–105 513
106–107 541
108–109 445
110–111 429
112–113 399
114–115 393
116–117 318
118–119 302
120–121 287
122–123 255
124–125 256
126–127 252
128–129 230
130–131 179
132–133 168
134–135 163
136–137 159
138–139 134
140–141 134
142–143 118
144–145 109
146–147 106
148–149 74
150–151 79
152–153 80
154–155 87
156–157 57
158–159 74
160–161 69
162–163 60
164–165 53
166–167 39
168–169 42
170–171 32
172–173 39
174–175 40
176–177 28
178–179 19
180–181 23
182–183 31
184–185 18
186–187 20
188–189 22
190–191 13
192–193 21
194–195 12
196–197 12
198–199 14
200–201 15
202–203 13
204–205 10
206–207 8
208–209 4
210–211 12
212–213 11
214–215 10
216 4
217+ 98
Download as CSV

Overview

Li Zhang is a researcher affiliated with Sun Yat-sen University in China, whose work is primarily situated in the field of medicine with a focus on oncology and pulmonary and respiratory medicine. Their research output includes substantial contributions to cancer research, molecular biology, and surgery.

Their research topics cover a variety of areas related to cancer and respiratory diseases, including:

  • Lung Cancer Treatments and Mutations
  • Lung Cancer Research Studies
  • Lung Cancer Diagnosis and Treatment
  • Cancer Genomics and Diagnostics
  • Cancer Immunotherapy and Biomarkers
  • Colorectal Cancer Treatments and Studies
  • Head and Neck Cancer Studies

Frequent publication venues for Li Zhang include:

  • Journal of Clinical Oncology
  • Annals of Oncology
  • Journal of Thoracic Oncology
  • Lung Cancer
  • Thoracic Cancer

Li Zhang has collaborated extensively with several researchers, including:

  • Wenfeng Fang
  • Yan Huang
  • Yunpeng Yang
  • Hongyun Zhao
  • Yuanyuan Zhao

Recent significant papers authored or coauthored by Li Zhang include:

  • Camrelizumab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (CAPTAIN-1st): a multicentre, randomised, double-blind, phase 3 trial, 2021, The Lancet Oncology
  • Apatinib Plus Gefitinib as First-Line Treatment in Advanced EGFR-Mutant NSCLC: The Phase III ACTIVE Study (CTONG1706), 2021, Journal of Thoracic Oncology
  • Ivonescimab Plus Chemotherapy in Non-Small Cell Lung Cancer With EGFR Variant, 2024, JAMA
  • Gemcitabine Plus Cisplatin Versus Fluorouracil Plus Cisplatin as First-Line Therapy for Recurrent or Metastatic Nasopharyngeal Carcinoma: Final Overall Survival Analysis of GEM20110714 Phase III Study, 2021, Journal of Clinical Oncology
  • Efficacy, safety, and biomarker analysis of Camrelizumab in Previously Treated Recurrent or Metastatic Nasopharyngeal Carcinoma (CAPTAIN study), 2021, Journal for ImmunoTherapy of Cancer

Li Zhang's work demonstrates a consistent focus on treatments and clinical trials for various types of cancer, particularly lung cancer and nasopharyngeal carcinoma, integrating chemotherapy, immunotherapy, targeted therapies, and biomarker analysis.

Best Publications

  • Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

    Caicun Zhou;Yi Long Wu;Gongyan Chen;Jifeng Feng

  • Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial

    Keunchil Park;Eng Huat Tan;Ken O'Byrne;Li Zhang

  • Selective chemical labeling reveals the genome-wide distribution of 5-hydroxymethylcytosine

    Chun Xiao Song;Keith E. Szulwach;Ye Fu;Qing Dai

  • Chemotherapy and radiotherapy in nasopharyngeal carcinoma: an update of the MAC-NPC meta-analysis

    Pierre Blanchard;Pierre Blanchard;Anne Lee;Sophie Marguet;Julie Leclercq

  • Systematic comparison of constitutive promoters and the doxycycline-inducible promoter.

    Jane Yuxia Qin;Jane Yuxia Qin;Li Zhang;Kayla L. Clift;Imge Hulur

  • Upregulation of PD-L1 by EGFR Activation Mediates the Immune Escape in EGFR-Driven NSCLC: Implication for Optional Immune Targeted Therapy for NSCLC Patients with EGFR Mutation

    Nan Chen;Wenfeng Fang;Jianhua Zhan;Shaodong Hong

  • Development and Validation of a Nomogram for Predicting Survival in Patients With Resected Non–Small-Cell Lung Cancer

    Wenhua Liang;Li Zhang;Gening Jiang;Qun Wang

  • Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial

    Yuankai Shi;Li Zhang;Xiaoqing Liu;Caicun Zhou

  • Sperm, but Not Oocyte, DNA Methylome Is Inherited by Zebrafish Early Embryos

    Lan Jiang;Jing Zhang;Jing-Jing Wang;Jing-Jing Wang;Lu Wang;Lu Wang

  • Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial.

    Roy S Herbst;Yan Sun;Wilfried E E Eberhardt;Paul Germonpré

  • Risk of COVID-19 for patients with cancer.

    Hanping Wang;Li Zhang

  • Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study.

    Jing Huang;Jianming Xu;Yun Chen;Wu Zhuang

  • Gemcitabine plus cisplatin versus fluorouracil plus cisplatin in recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 trial

    Li Zhang;Yan Huang;Shaodong Hong;Yunpeng Yang

  • Nestin is required for the proper self-renewal of neural stem cells.

    Donghyun Park;Donghyun Park;Andy Peng Xiang;Frank Fuxiang Mao;Frank Fuxiang Mao;Li Zhang

  • Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of Alectinib in Untreated ALK-Positive Advanced Non–Small Cell Lung Cancer in the Global Phase III ALEX Study

    D. Ross Camidge;Rafal Dziadziuszko;Solange Peters;Tony Mok

  • Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): a randomised, double-blind trial

    Yi Long Wu;Jin Soo Lee;Sumitra Thongprasert;Chong Jen Yu

  • Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials

    Wenfeng Fang;Yunpeng Yang;Yuxiang Ma;Shaodong Hong

  • Phase III Trial of Ipilimumab Combined With Paclitaxel and Carboplatin in Advanced Squamous Non–Small-Cell Lung Cancer

    Ramaswamy Govindan;Aleksandra Szczesna;Myung Ju Ahn;Claus Peter Schneider

  • EBV-driven LMP1 and IFN-γ up-regulate PD-L1 in nasopharyngeal carcinoma: Implications for oncotargeted therapy

    Wenfeng Fang;Jianwei Zhang;Shaodong Hong;Jianhua Zhan

Frequent Co-Authors

Yi-Long Wu
Yi-Long Wu Guangdong Provincial People’s Hospital
Caicun Zhou
Caicun Zhou Tongji University
Bruce T. Lahn
Bruce T. Lahn University of Chicago
Tony Mok
Tony Mok Chinese University of Hong Kong
Gang Chen
Gang Chen Guangxi Medical University
James Chih-Hsin Yang
James Chih-Hsin Yang National Taiwan University
Jifeng Feng
Jifeng Feng Nanjing Medical University
Kenneth J. O'Byrne
Kenneth J. O'Byrne Queensland University of Technology
Luis Paz-Ares
Luis Paz-Ares Complutense University of Madrid
Michael Boyer
Michael Boyer University of Utah

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Are you exploring alternative career routes or flexible study options related to Medicine in the USA? Online education now offers many accredited pathways for both newcomers and experienced professionals in healthcare and related fields.

For registered nurses looking to advance their careers, consider targeted bridge programs like rn to fnp programs or rn to bsn online with no clinicals. These degrees provide a fast track to higher qualifications, often with flexible schedules and minimal on-site requirements.

If you’re interested in the science behind health and wellness, the best online food science degree programs can open doors to careers in nutrition, research, or food safety. Aspiring health administrators can pursue leadership by enrolling in whats the best online mha program for working adults, which is ideal for those balancing professional commitments.

With flexible online options, you can customize your learning journey, access diverse healthcare fields, and build a fulfilling career that makes a difference.

Best Scientists Citing Li Zhang

Trending Scientists

Recently Published Articles